. Author manuscript; available in PMC: 2018 Feb 1.

Published in final edited form as: Lancet Diabetes Endocrinol. 2017 Jun 11;5(8):597–609. doi: 10.1016/S2213-8587(17)30194-8

Table 2.

Repeated measures analysis of cIMT

	Averaged mean far-wall cIMT (primary outcome)			Averaged maximal far-wall cIMT (tertiary outcome)
	Metformin	Placebo	Difference (95% CI); p value	Metformin	Placebo	Difference (95% CI); p value
Baseline (mm)	0·773 (0·140)	0·791 (0·183)	..	0·910 (0·162)	0·926 (0·225)	..
12 months (mm)	0·782 (0·147)	0·788 (0·174)	..	0·920 (0·175)	0·939 (0·239)	..
24 months (mm)	0·792 (0·145)	0·823 (0·187)	..	0·936 (0·161)	0·984 (0·251)	..
36 months (mm)	0·793 (0·134)	0·820 (0·177)	..	0·949 (0·167)	0·999 (0·257)	..
Main analysis^*
Slope (95% CI; mm per year)	0·006 (0·001 to 0·011)	0·010 (0·006 to 0·015)	−0·005 (−0·012 to 0·002); p=0·1664	0·012 (0·005 to 0·019)	0·025 (0·018 to 0·032)	−0·013 (−0·024 to −0·003; p=0·0093)

Data are mean (SD), unless otherwise indicated. Analyses are for modified intention-to-treat of participants with at least one measurement after baseline. cIMT=common carotid artery intima-media thickness.

Adjusted for baseline age, sex, cIMT, smoking status, systolic blood pressure, BMI, HbA_1c, and LDL cholesterol.